Actively Recruiting

Phase 1
Age: 18Years - 75Years
All Genders
NCT06857227

A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Rheumatoid Arthritis

Led by Sichuan Baili Pharmaceutical Co., Ltd. · Updated on 2025-04-15

54

Participants Needed

1

Research Sites

141 weeks

Total Duration

On this page

Sponsors

S

Sichuan Baili Pharmaceutical Co., Ltd.

Lead Sponsor

B

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Collaborating Sponsor

AI-Summary

What this Trial Is About

This study is a randomized controlled phase I clinical study with safety, efficacy, and pharmacokinetic/pharmacodynamic characteristics in patients with rheumatoid arthritis.

CONDITIONS

Official Title

A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Rheumatoid Arthritis

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Able to understand and voluntarily sign informed consent
  • Any gender
  • Aged 18 to 75 years
  • Life expectancy longer than 6 months
  • Diagnosed with rheumatoid arthritis by 1987 or 2010 ACR/EULAR criteria
  • Moderate to severe active rheumatoid arthritis at screening
  • Stable standard-of-care treatment for at least 30 days before first dose
  • If previously treated with antirheumatic drugs other than methotrexate, leflunomide stopped at least 8 weeks prior or cholestyramine used for 14 days
  • Erythrocyte sedimentation rate (ESR) over 28 mm/hr or C-reactive protein (CRP) over 10 mg/L
  • Positive rheumatoid factor or anti-cyclic citrullinated peptide antibodies
  • Presence of CD19+ B cells in peripheral blood
  • Rheumatoid arthritis diagnosis for more than 6 months
  • Organ function meets requirements before first administration
  • Fertile participants must use effective contraception from 7 days before first dose until 24 weeks after treatment ends and avoid donating eggs/sperm for 1 year
  • Negative pregnancy test within 7 days before first dose for females of childbearing potential
  • Able and willing to comply with study visits, treatment, lab tests, and procedures
Not Eligible

You will not qualify if you...

  • Diagnosis of another autoimmune rheumatic disease
  • B cell-targeted therapy within 6 months before GNC-038 treatment
  • CAR-T therapy within 6 months before GNC-038 treatment
  • Use of anti-TNF drugs within 8 weeks before dosing
  • Use of JAK inhibitors within 2 weeks before dosing
  • Use of antimalarial drugs, sulfasalazine, penicillamine, or similar within 4 weeks before dosing
  • Use of phytochemicals within 4 weeks before dosing
  • Use of other biological agents or non-B cell depleting investigational drugs exceeding 5 half-lives before dosing
  • Intra-articular injection within 4 weeks before study entry
  • Participation in other investigational drug trials within 28 days or 5 half-lives
  • ACR functional class IV or bedridden/wheelchair-bound
  • History of major organ, hematopoietic stem cell, or bone marrow transplantation
  • Active hepatitis B, hepatitis C, HIV, or syphilis infection
  • Cardiovascular disease history within 6 months before screening
  • Poorly controlled high blood pressure
  • Prolonged QT interval at rest
  • Recent significant bleeding or need for continuous anticoagulant therapy
  • Allergy to humanized antibodies or GNC-038 components
  • Pregnant or breastfeeding women
  • Recent suicidal thoughts considered high risk
  • Malignant tumor diagnosis within 5 years
  • Poor compliance or unwillingness to follow study
  • History of splenectomy
  • Alcohol or drug abuse in past 12 months
  • Active infection needing antibiotics within 2 weeks before or during screening
  • History of severe or widespread viral infection
  • Possible active tuberculosis infection

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Renji Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China

Actively Recruiting

Loading map...

Research Team

S

Sa Xiao, PHD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Rheumatoid Arthritis | DecenTrialz